A B S T R A C T We describe studies of the molecular defect in 1,25-dihydroxyvitamin D3 [1, 
INTRODUCTION
Rickets due to resistance to the action of 1,25-dihydroxyvitamin D [1,25-(OH)2D]' has been described in several families (1) (2) (3) (4) (5) (6) (7) (8) (9) . This condition has come to be known as vitamin D-dependent rickets, type II, a term that fails to convey the concept that this disorder is a form of steroid hormone resistance. The characteristic clinical features are defective bone mineralization, usually beginning as rickets in childhood, impaired intestinal calcium absorption, and increased plasma levels of 1,25-(OH)2D. In contrast to patients with vitamin D-dependent rickets, type I, whose plasma levels of 1,25-(OH)2D are decreased and whose bone disease can be cured by physiological replacement doses of 1,25-(OH)2D3, these patients either respond only to pharmacological doses of the hormone (1-3, 6) or do not respond at all with the doses tested (7) (8) (9) .
Studies of the molecular nature of the defects in this disorder were initially limited due to the difficulty of studying human intestinal mucosa, the primary site of hormone action. More recently, methods have been developed to measure 1,25-(OH)2D3 receptors in cytosol from cultured skin fibroblasts (10) and to assess retention of [3H]1,25-(OH)2D3 in fibroblast nuclei following binding in dispersed whole cells (11) . Eil et al. (12) initially used the latter method to evaluate two families with vitamin D-dependent rickets, type II, and reported an apparent lack of nuclear retention of the steroid. More recently, Liberman, Eil, and Marx (13) have presented evidence for genetic heterogeneity in fibroblasts from affected patients with some families having deficiency of cytosol receptor binding, others having impaired nuclear retention of the steroid, and at least one family having no identifiable abnormality.
In the present report a method of assessing 1,25-(OH)2D3 action in cultured skin fibroblasts is described. Normal skin fibroblasts respond to 1,25-(OH)2D3 treatment by enhancement of 25-hydroxyvitamin D-24-hydroxylase (24-hydroxylase) . Using this method the nature of the molecular defect in 1,25-(OH)2D3 action is evaluated in cultured skin fibroblasts from a previously reported patient with vitamin D-dependent rickets, type II (4) , in whom 1,25-(OH)2D3 receptor binding is normal.
METHODS
Materials. Materials used for cell culture have been described previously (14) , except that fetal and newborn calf sera were obtained from Gibco Laboratories (Grand Island, NY). Tissue culture dishes (15 cm (15) . [ Cell culture. The fibroblast strains used in these experiments were established from explants of skin and are listed in Table I . Cell strain 460 is from a patient previously reported to have vitamin D-dependent rickets, type II (4). Cell strains 87 and 98 are from her father and mother, respectively. Cell strain 82 is from a patient with the tentative Cytosol-binding assay. Cells were scraped from plastic dishes into cold Tris-saline (50 mM Tris-Cl, 150 mM NaCl, pH 7.4). The cells were pelleted by centrifugation at 800 g, rinsed twice in Tris-saline, and resuspended in 2-3 vol of TEDMK buffer (10 mM Tris-Cl, 1.5 mM EDTA, 1 mM dithiothreitol, 10 mM sodium molybdate, 300 mM KCI, pH 7.4). The cell suspension was subjected to sonic disruption in the cup horn attachment of a model W-185 sonifier cell disrupter (Heat Systems-Ultrasonics, Inc., Plainview, NY) using six 10-s bursts, and the sonicate was centrifuged at 100,000 g for 1 h at 0°C. The resultant high salt extract supernatant was saved and, though it probably contains receptors from both the cytosolic and nuclear compartment, will be referred to as cytosol. 200 ul of the cytosol were added to polypropylene microfuge tubes (capacity 1. 
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The tubes were incubated for 4 h at 0°C, and bound and free steroid were separated by hydroxylapatite as described by Wecksler and Norman (16) . In this procedure 0.4 ml of a 50% slurry of hydroxylapatite in 10 mM Tris-CI 0.1 M KCI (pH 7.5) were added, the tubes were mixed, and the hydroxylapatite pelleted by centrifugation for 2-3 s in a microfuge. The hydroxylapatite pellets were washed three times with 10 mM Tris-Cl 0.5% Triton X-100 (pH 7.5), extracted twice with 0.9 ml ethanol, and counted in 10 ml of Budget-Solve. Protein was measured by the method of Lowry et al. (17) using BSA as standard. The amount of high affinity binding or Bm.. was estimated by linear regression of the plot of total binding using the higher steroid concentrations. Half-maximal saturation was estimated from this same plot as the concentration of steroid at which the binding was half-maximal. (18) . Cells cultured as described above were harvested from the 15-cm Falcon dishes by addition of 4 ml of stock trypsin-EDTA solution diluted 1:1 with PBS followed by incubation at 370C for 5 min. The dishes were removed from the incubator and tapped gently, and the cells were detached by gentle trituration with a Pasteur pipette. The cells were pelleted by centrifugation at 800 g and resuspended with mixing in cold PBS. Following repeat pelleting at 800 g, the cells were resuspended in bicarbonate-free Eagle's minimal essential medium buffered with Hepes instead of tricine at a concentration of 1-2 X 106 cells/ml. 5 ml of the cell suspension were incubated in 15-ml polypropylene tubes containing 1 nM [8H]1,25-(OH)2D3 with or without 250 nM 1,25-(OH)2D3 at 370C for 45 min in a shaking water bath. The tubes were mixed on a vortex apparatus every 10 min during the incubation. Following the incubation the cells were centrifuged at 800 g and rinsed by resuspension and centrifugation five times in 5 ml of 50 mM Tris-Cl (pH 7.4) containing 150 mM NaCI and 0.2% BSA, and twice with 5 ml of 150 mM NaCl. The final supernatant was aspirated, and the cell pellet was resuspended by mixing in 5 ml Tris-sucrose buffer (20 mM Tris-Cl, 0.32 M sucrose, and 1 mM MgCl2, pH 7.5). The cell suspension was transferred to glass tubes, and the remainder of the nuclear binding procedure was as described (18) . In brief, following incubation in hypotonic buffer (20 mM Tris-Cl, 0.5 mM MgCl2, and 1 mM CaC12, pH 7.5) for 15 min to allow cell swelling, the cells were disrupted by passage 10 times through a 25-gauge needle. The solution was made isotonic by the addition of hypertonic Tris-sucrose buffer (20 mM Tris-Cl, 2.1 M sucrose, 0.5 mM MgCl2, and 1 mM CaCl2, pH 7.5), the nuclei were collected by centrifugation at 2,000 g for 20 min, and the nuclear pellet was resuspended in 5 ml Tris-sucrose buffer. Following repeat centrifugation, the nuclei were resuspended in 2.6 ml Tris-sucrose and layered over 2.6 ml of hypertonic Tris-sucrose buffer. The mixture was centrifuged at 100,000 g for 1 h, the resultant purified nuclear pellet was resuspended by passage through a 25-gauge needle, and aliquots for DNA quantitation and radioactivity measurement were taken. Specific nuclear binding was estimated by subtraction of the amount bound in the incubation containing added nonradioactive 1,25-(OH)2D3 from that bound in the incubation with radioactive hormone alone.
Density gradients. Cells cultured as described above were harvested from 15-cm Falcon dishes with trypsin-EDTA solution and incubated at a density of 1-2 X 10' cells/ ml medium with 1 nM [3H]1,25-(OH)2D3 with or without 250 nM 1,25-(OH)2D3 at 37°C for 45 min as described for the nuclear localization studies above. After rinsing, the cell pellets were resuspended in an equal volume of TEDMK buffer and subjected to sonic disruption as described for the cytosol-binding assay. (Fig. 3 A) (Fig. 3 B) . The major metabolite peak coeluted with authentic 24,25-(OH)2D3.
When the fractions in the region of the peak coeluting with 24,25-(OH)2D3 were pooled and rechromatographed on straight-phase HPLC as described in the Methods, 87% of the radioactivity from the reversed-phase HPLC peak coeluted with authentic 24,25-(OH)2D3. Fig. 3 (Fig. 4 A) . When par- (Fig. 5 A) and with amount of protein to 0.1 mg/assay (Fig. 5 B) . A standard assay time of 30 min was chosen.
When control fibroblasts were incubated with increasing concentrations of 1,25-(OH)2D3 for 8 h before harvesting, the formation of 24,25-(OH)2D3 was increased by concentrations, of 1,25-(OH)2D3 as low as 0.02 nM (Fig. 6) (Fig. 6) . In other studies not shown, doses of 1,25-(OH)2D3 as droxylase activity could be detected as early as 2 h and appeared to plateau between 6 and 12 h. (Fig.  7) . A standard time of 8 h treatment with 1,25-(OH)2D3 was chosen for comparing cell strains.
The effects of 1,25-(OH)2D3 on 24-hydroxylase activity in control fibroblast strains, and in fibroblasts from the patient with vitamin D-dependent rickets, type II, and from her parents are shown in Fig. 8 The concept of a postreceptor defect in steroid hormone action was first proposed by studies of glucocorticoid-resistant lymphoma cells (22) (23) (24) (25) . Absent binding, decreased amount of receptor, and a qualitatively abnormal receptor are defects commonly seen in these glucocorticoid-resistant cells, while the inability to identify a receptor abnormality is rare (22) (23) (24) (25) . Amrhein et al. (26) were the first to report the presence of normal androgen receptor binding in a family with testicular feminization and to raise the possibility of a postreceptor defect in androgen action. However, when more sensitive techniques were developed to assess qualitative abnormalities of the androgen receptor, only a small fraction of the families with androgen resistance had no identifiable receptor abnormality (27) . And, in fact, the first family reported to have receptor-positive androgen resistance (26) has recently been shown to have a qualitatively abnormal androgen receptor (28) . Thus, defects in steroid hormone action at a postreceptor site are uncommon.
One of the limitations of prior evaluations of receptor-positive steroid hormone resistance in man has been the lack of a marker of hormone action in cultured cells. In the studies of fibroblasts from families with androgen resistance (27) and from the single family with glucocorticoid resistance (29) (30) . Although the primary site of induction of 24-hydroxylase activity is thought to be the kidney (31) , recent studies in the rat suggest that extrarenal 24-hydroxylase activity accounts for a third of the 24,25-(OH)2D3 production, and that the extrarenal 24-hydroxylase is also under regulatory control by 1,25-(OH)2D3 (32) . The sites of extrarenal 24- hydroxylase activity are incompletely defined. Initial studies of 24-hydroxylase activity in cultured cells were limited to primary cultures of chick kidney cells (38) . Primary cultures of human bone cells also have 24-hydroxylase activity that is responsive to 1,25-(OH)2D3 (34) , and a number of established mammalian cell lines possess both receptors for 1,25-(OH)2D3 and the capacity to respond to the hormone by induction of 24-hydroxylase activity (35, 36) . Because of these findings we assessed the effects of. 1,25-(OH)2D3 on the 24-hydroxylase activity in normal and patient skin fibroblasts. Since the presence of a normal 1,25-(OH)2D3 receptor and presumably normal receptor function are required for induction of 24-hydroxylase (9, 36), we conclude that impaired stimulation of the enzyme in the presence of normal receptor binding is evidence for postreceptor resistance to the action of the hormone.
The relation of the impaired induction of 24-hydroxylase activity in fibroblasts to the in vivo formation of 24,25-(OH)2D3 in the patient is unclear. Although receiving treatment with 25-(OH)D3 to raise the plasma level of 25-(OH)D3 to five times normal, the patient's plasma level of 24,25-(OH)2D3 was in the normal range (unpublished observations). (No pretreatment level was obtained.) This "normal" value may be inappropriately low for an elevated plasma level of 1,25-(OH)2D3 and the increased level of the substrate (37) . Alternatively the low 24-hydroxylase in the fibroblasts may not reflect the activity of the enzyme in the renal tubular epithelium, the primary site of formation of plasma 24,25-(OH)2D3, but rather may be more indicative of the enzyme in bone or other extrarenal tissues. There is precedent for this impaired induction of 24-hydroxylase in fibroblasts in spite of "normal" 24,25-(OH)2D levels in vivo in the previously mentioned patient with receptor-negative vitamin D-dependent rickets, type II (9) . In this patient the 24,25-(OH)2D level was higher than the mean level in normal subjects (9) .
The finding of impaired formation of 24,25-(OH)2D3 in cells from a patient with osteomalacia raises the question of the importance of this vitamin D metabolite in normal vitamin D action. Although some investigators have concluded that 24,25-(OH)2D3 does not have effects distinct from those of 25-(OH)D3 (38) , others have concluded that 24,25-(OH)2D3 plays an important role in mineralization of bone (39) , in suppression of parathyroid hormone secretion (40) , in skeletal maturation during embryogenesis (41, 42) , and in ameliorating the effect of nephrectomy on bone resorption (43) .
